Search

Your search keyword '"Tsuchiya, Kaoru"' showing total 406 results
Start Over Author "Tsuchiya, Kaoru" Publication Year Range Last 10 years
406 results on '"Tsuchiya, Kaoru"'

1. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

Author

Mori, Nami, Tamaki, Nobuharu, Takaki, Shintaro, Tsuji, Keiji, Tada, Toshifumi, Nakamura, Shinichiro, Ochi, Hironori, Mashiba, Toshie, Doisaki, Masao, Marusawa, Hiroyuki, Kobashi, Haruhiko, Fujii, Hideki, Ogawa, Chikara, Nonogi, Michiko, Arai, Hirotaka, Uchida, Yasushi, Urawa, Naohito, Narita, Ryoichi, Akahane, Takehiro, Kondo, Masahiko, Yasui, Yutaka, Tsuchiya, Kaoru, Izumi, Namiki, and Kurosaki, Masayuki

Published
2024
Full Text
View/download PDF

2. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)

Author

Kobayashi, Kazufumi, Ogasawara, Sadahisa, Itobayashi, Ei, Okubo, Tomomi, Itokawa, Norio, Nakamura, Kazuyoshi, Moriguchi, Michihisa, Watanabe, Shunji, Ikeda, Masafumi, Kuroda, Hidekatsu, Kawaoka, Tomokazu, Hiraoka, Atsushi, Yasui, Yutaka, Kuzuya, Teiji, Sato, Rui, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Nakamura, Masato, Kiyono, Soichiro, Kanogawa, Naoya, Kondo, Takayuki, Nakamoto, Shingo, Ozawa, Yoshihito, Tsuchiya, Kaoru, Atsukawa, Masanori, Aikata, Hiroshi, Aramaki, Takeshi, Oka, Shiro, Morimoto, Naoki, Kurosaki, Masayuki, Itoh, Yoshito, Izumi, Namiki, and Kato, Naoya

Published
2024
Full Text
View/download PDF

3. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease

Author

Tamaki, Nobuharu, Higuchi, Mayu, Kurosaki, Masayuki, Loomba, Rohit, Izumi, Namiki, Group, MRCH Liver Study, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, and Itakura, Jun

Subjects
Liver Cancer, Rare Diseases, Prevention, Chronic Liver Disease and Cirrhosis, Heart Disease, Cancer, Digestive Diseases, Hepatitis, Liver Disease, Cardiovascular, Oral and gastrointestinal, Good Health and Well Being, Carcinoma, Hepatocellular, Cardiovascular Diseases, Humans, Liver Cirrhosis, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, MRCH Liver Study Group, Clinical Sciences, Gastroenterology & Hepatology
Abstract

Nonalcoholic fatty liver disease (NAFLD) has affected more than one-fourth of the global population, thus emerging as a worldwide health and economic burden.1 The common causes of death in patients with NAFLD include cardiovascular disease (CVD), decompensation, and hepatocellular carcinoma (HCC). However, identifying the risk of these complications in patients with NAFLD remains an unmet need in clinical practice.

Published
2022

4. Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality

Author

Higuchi, Mayu, Tamaki, Nobuharu, Kurosaki, Masayuki, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Hayakawa, Yuka, Osawa, Leona, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Loomba, Rohit, Enomoto, Nobuyuki, and Izumi, Namiki

Subjects
Liver Cancer, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Rare Diseases, Liver Disease, Cancer, Clinical Research, Good Health and Well Being, Carcinoma, Hepatocellular, Elasticity Imaging Techniques, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Magnetic Resonance Imaging, Retrospective Studies, Clinical Sciences, Pharmacology and Pharmaceutical Sciences, Gastroenterology & Hepatology
Abstract

BackgroundMagnetic resonance elastography (MRE) has the highest diagnostic accuracy for liver fibrosis; however, the association between MRE-associated liver stiffness and the development of hepatic and extrahepatic complications as well as mortality remains unclear.AimIn this study, we investigated the longitudinal association between MRE-associated liver stiffness and complications and mortality.MethodsThis retrospective study included 2373 consecutive patients with chronic liver disease. All patients received standard of care and the development of complications was assessed every 1-6 months.ResultsNewly diagnosed hepatocellular carcinoma (HCC), decompensation, major adverse cardiovascular events (MACE), extrahepatic cancer and death were observed in 99, 117, 73, 77 and 170 patients respectively. In multivariable analysis, the adjusted hazard ratios (aHR) (95% confidence interval [CI]) for HCC, decompensation, MACE, extrahepatic cancer and mortality were 1.28 (1.2-1.4), 1.34 (1.3-1.4), 0.96 (0.9-1.1), 1.00 (0.9-1.1) and 1.17 (1.1-1.2), respectively, with each 1-kPa increase in liver stiffness. Similarly, the aHR (95% CI) for HCC, decompensation, MACE, extrahepatic cancer and mortality were 4.20 (2.2-8.2), 67.5 (9.2-492), 0.83 (0.4-1.7), 0.90 (0.5-1.7) and 2.90 (1.6-5.4), respectively, in patients with cirrhosis (>4.7 kPa) compared to those with minimal fibrosis (

Published
2022

5. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

Author

Takaki, Shintaro, Kurosaki, Masayuki, Mori, Nami, Tsuji, Keiji, Ochi, Hironori, Marusawa, Hiroyuki, Nakamura, Shinichiro, Tada, Toshifumi, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Kusakabe, Atsunori, Furuta, Koichiro, Kobashi, Haruhiko, Arai, Hirotaka, Nonogi, Michiko, Tamada, Takashi, Hasebe, Chitomi, Ogawa, Chikara, Sato, Takashi, Tamaki, Nobuharu, Yasui, Yutaka, Tsuchiya, Kaoru, and Izumi, Namiki

Published
2023
Full Text
View/download PDF

6. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H

Published
2023
Full Text
View/download PDF

7. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup

Author

Tamaki, Nobuharu, Kurosaki, Masayuki, Takahashi, Yuka, Itakura, Yoshie, Kirino, Sakura, Inada, Kento, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Loomba, Rohit, and Izumi, Namiki

Subjects
Biochemistry and Cell Biology, Biological Sciences, Medicinal and Biomolecular Chemistry, Chemical Sciences, Microbiology, Clinical Trials and Supportive Activities, Prevention, Digestive Diseases, Clinical Research, Liver Disease, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Oral and gastrointestinal, Good Health and Well Being, Aged, Aged, 80 and over, Antigens, Neoplasm, Biomarkers, Cross-Sectional Studies, Elasticity Imaging Techniques, Female, Humans, Liver Cirrhosis, Male, Membrane Glycoproteins, Middle Aged, Plant Lectins, Prospective Studies, ROC Curve, Receptors, N-Acetylglucosamine, WFA(+)-M2BP, FIB-4, liver fibrosis, screening, WFA+-M2BP, Other Chemical Sciences, Genetics, Other Biological Sciences, Chemical Physics, Biochemistry and cell biology, Medicinal and biomolecular chemistry
Abstract

Chronic liver disease is generally widespread, and a test for screening fibrotic subjects in a large population is needed. The ability of Wisteria floribunda agglutinin-positive mac-2 binding protein (WFA+-M2BP) to detect significant fibrosis was investigated in health checkup subjects in this research. Of 2021 health checkup subjects enrolled in this prospective cross-sectional study, those with WFA+-M2BP ≥ 1.0 were defined as high risk. Liver fibrosis was evaluated using magnetic resonance elastography (MRE) in subjects with high risk. The primary outcome was the positive predictive value (PPV) of WFA+-M2BP for significant fibrosis (liver stiffness ≥ 2.97 kPa by MRE). This trial was registered with the UMIN clinical trial registry, UMIN000036175. WFA+-M2BP ≥ 1.0 was observed in 5.3% of the 2021 subjects. The PPV for significant fibrosis with the threshold of WFA+-M2BP at ≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4, and ≥1.5 was 29.2%, 36.4%, 43.5%, 42.9%, 62.5%, and 71.4%, respectively. A WFA+-M2BP of 1.2 was selected as the optimal threshold for significant fibrosis among high-risk subjects, and the PPV, negative predictive value, sensitivity, and specificity for significant fibrosis were 43.5%, 84.0%, 71.4%, and 61.8%, respectively. WFA+-M2BP ≥ 1.2 was significantly associated with significant fibrosis, with an odds ratio (OR) of 4.04 (95% confidence interval (CI): 1.1-16, p = 0.04), but not FIB-4 ≥ 2.67 (OR: 2.40, 95%CI: 0.7-8.6, p-value = 0.2). In conclusion, WFA+-M2BP is associated with significant fibrosis and could narrow down potential subjects with liver fibrosis. The strategy of narrowing down fibrosis subjects using WFA+-M2BP may be used to screen for fibrotic subjects in a large population.

Published
2021

8. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Author

Tamaki, Nobuharu, Tada, Toshifumi, Kurosaki, Masayuki, Yasui, Yutaka, Ochi, Hironori, Mashiba, Toshie, Sakamoto, Azusa, Marusawa, Hiroyuki, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kobashi, Haruhiko, Kusakabe, Atsunori, Furuta, Koichiro, Arai, Hirotaka, Nonogi, Michiko, Ogawa, Chikara, Sato, Takashi, Tamada, Takashi, Nakamura, Shinichiro, Hasebe, Chitomi, Tsuchiya, Kaoru, and Izumi, Namiki

Published
2022
Full Text
View/download PDF

10. Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Author

Kudo, Masatoshi, primary, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Nakagawa, Yuki, additional, and Ikeda, Masafumi, additional

Published
2024
Full Text
View/download PDF

12. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

Author

Hayakawa, Yuka, Tsuchiya, Kaoru, Kurosaki, Masayuki, Yasui, Yutaka, Kaneko, Shun, Tanaka, Yuki, Ishido, Shun, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Nobusawa, Tsubasa, Matsumoto, Hiroaki, Kakegawa, Tatsuya, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Tamaki, Nobuharu, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Okamoto, Ryuichi, and Izumi, Namiki

Published
2022
Full Text
View/download PDF

13. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease.

Author

Tamaki, Nobuharu, Wakabayashi, Shun‐Ichi, Kimura, Takefumi, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Huang, Daniel Q., Umemura, Takeji, Kurosaki, Masayuki, and Izumi, Namiki

Subjects
MAJOR adverse cardiovascular events, GLYCEMIC control, GLYCOSYLATED hemoglobin, HEPATOCELLULAR carcinoma, LIVER diseases
Abstract

Aims: Optimizing glycemic control may prevent liver‐related events and major adverse cardiovascular events (MACE) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the optimal hemoglobin A1c (HbA1c) threshold associated with a lower risk of complications, particularly liver‐related events as well as MACE is unknown. Methods: We investigated a nationwide population‐based cohort and identified 633 279 patients with MASLD, with a mean follow‐up of 4.2 years. Hemoglobin A1c levels were measured annually. The primary endpoint was the risk of liver‐related events and MACE and to determine the optimal HbA1c level associated with the risk of complications. Results: Mean HbA1c (per 1%) was associated with liver‐related events (subdistribution hazard ratio [sHR] 1.26; 95% confidence interval [CI], 1.12–1.42) as well as MACE (sHR 1.36; 95% CI, 1.32–1.41) after adjustment for confounders. Multivariable sHR (95% CI) for HbA1c of <5.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, and ≥9.0% (reference, 5.0%–5.9%) were 14 (9.1–22), 1.70 (1.2–2.3), 3.32 (2.3–4.8), 3.81 (2.1–6.8), and 4.83 (2.4–9.6) for liver‐related events, and 1.24 (0.8–1.8), 1.27 (1.2–1.4), 1.70 (1.5–2.0), 2.36 (1.9–2.9), and 4.17 (3.5–5.0) for MACE. An HbA1c level of 7% was selected as the optimal threshold for predicting complications (sHR 2.40 [1.8–3.2] for liver‐related events and 1.98 [1.8–2.2] for MACE). Conclusion: The risk of liver‐related events as well as MACE increased in a dose‐dependent fashion with an increase in HbA1c levels, except for patients with HbA1c <5.0% for liver‐related events. An HbA1c level of 7% was the optimal threshold associated with a lower risk of complications and may be utilized as a target for glycemic control in patients with MASLD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B

Author

Tamaki, Nobuharu, primary, Higuchi, Mayu, additional, Keitoku, Taisei, additional, Yamazaki, Yudai, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Okada, Risa, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Kanto, Tatsuya, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2024
Full Text
View/download PDF

15. Impact of immune‐related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Suzuki, Keito, primary, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Matsumoto, Hiroaki, additional, Yamazaki, Yudai, additional, Uchihara, Naoki, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada‐Shimizu, Michiko, additional, Keitoku, Taisei, additional, Okada, Risa, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Tamaki, Nobuharu, additional, Nakanishi, Hiroyuki, additional, Takahashi, Yuka, additional, Asahina, Yasuhiro, additional, Okamoto, Ryuichi, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2024
Full Text
View/download PDF

18. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.

Author

Kudo, Masatoshi, Tsuchiya, Kaoru, Shao, Yu-Yun, Finn, Richard S., Galle, Peter R., Ducreux, Michel, Cheng, Ann-Lii, Yamashita, Tatsuya, Koga, Hironori, Take, Ryosuke, Yamada, Kyoko, Asakawa, Takashi, Nakagawa, Yuki, and Ikeda, Masafumi

Subjects
HEPATOCELLULAR carcinoma, OVERALL survival, PROGRESSION-free survival, BEVACIZUMAB, SPECIAL events
Abstract

Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs). Methods: Patients in IMbrave150 who were randomized to atezolizumab + bevacizumab and received treatment for ≥6 months (to reduce immortal time bias) were included in group A-1 if bevacizumab had ever been skipped due to bevacizumab AESIs or to group A-2 otherwise. Efficacy analyses included overall survival (OS) and progression-free survival (PFS) by whether bevacizumab was skipped (group A-1 vs. A-2). PFS was evaluated per independent review facility (IRF)-assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and HCC-modified RECIST (IRF-HCC mRECIST). Safety was also evaluated. Results: Of the 210 patients who received ≥6 months of atezolizumab + bevacizumab, 69 were assigned to group A-1 and 141 to A-2. At data cutoff (August 20, 2020), hazard ratio (HR) for OS was 1.04 (95% CI: 0.64, 1.69) for group A-1 versus A-2. HR for PFS was 1.07 (95% CI: 0.74, 1.55) per IRF-assessed RECIST 1.1 and 1.10 (95% CI: 0.76, 1.59; 15.5 vs. 9.7 months) per IRF-HCC mRECIST for group A-1 versus A-2. Safety profiles for atezolizumab and bevacizumab were largely similar between groups. More group A-1 patients had grade 3/4 adverse events. A separate analysis investigating the impact of immortal time bias in patients who received ≥3 months of atezolizumab + bevacizumab supported the appropriateness of the ≥6-month landmark analysis. Discussion/Conclusion: Efficacy was similar between patients who skipped bevacizumab due to bevacizumab AESIs and those who did not. Although this comparison was nonrandomized and exploratory, results suggest that skipping bevacizumab due to bevacizumab AESIs did not considerably impact the efficacy and safety of atezolizumab + bevacizumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis.

Author

Tamaki, Nobuharu, Takaura, Kenta, Higuchi, Mayu, Yasui, Yutaka, Itakura, Jun, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Izumi, Namiki, and Kurosaki, Masayuki

Subjects
HEPATIC fibrosis, CHRONIC active hepatitis, OLDER people, LIVER biopsy, LIVER diseases
Abstract

Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas with a high number of elderly people suffering from chronic liver disease has yet to be determined. Methods: This is a prospective study that included 373 consecutive patients who underwent a liver biopsy and had their ELF score measured on the same day. The diagnostic accuracy of the ELF score for liver fibrosis and the effect of age on the ELF score were investigated. Results: The median (interquartile) ELF scores in F0, F1, F2, F3, and F4 are 8.7 (8.2–9.2), 9.3 (8.8–10.0), 10.1 (9.4–10.7), 10.7 (9.9–11.2), and 12.0 (11.2–12.7), respectively. ELF scores increased with increasing liver fibrosis stage (p < 0.001). The diagnostic accuracy of the ELF score and FIB-4 for significant fibrosis (F2–4) and advanced fibrosis (F3–4) was comparable, but the ELF score had a higher diagnostic accuracy for cirrhosis (F4) than FIB-4. When patients were stratified by age of 60 years, the median ELF score did not differ by age in F2, F3, and F4. However, the median FIB-4 increased in patients with ≥60 years compared to those with <60 years in all fibrosis stages. Conclusions: ELF score has high diagnostic accuracy for liver fibrosis, regardless of age, and it could be used as a primary screening method. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease.

Author

Suzuki, Keito, Tamaki, Nobuharu, Kurosaki, Masayuki, Takahashi, Yuka, Yamazaki, Yudai, Uchihara, Naoki, Tanaka, Yuki, Miyamoto, Haruka, Yamada, Michiko, Keitoku, Taisei, Okada, Risa, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, and Izumi, Namiki

Subjects
NON-alcoholic fatty liver disease, FATTY liver, WAIST circumference, JAPANESE people, LIVER diseases
Abstract

Aim: A multisociety consensus group proposed a new nomenclature for metabolic dysfunction‐associated steatotic liver disease (MASLD). Although patients with nonalcoholic fatty liver disease (NAFLD) are expected to be reclassified as patients with MASLD under the new nomenclature, the concordance between MASLD and NAFLD remains unclear. Moreover, waist circumference could be adjusted by ethnicity for diagnosing MASLD; however, there are limited data on the optimal waist circumference in the Japanese population. Methods: This cross‐sectional study was conducted on 3709 Japanese patients with NAFLD. The primary endpoint was the prevalence of MASLD in patients with NAFLD. The difference between the original waist circumference criteria (>94 cm for men and >80 cm for women) and the Japanese metabolic syndrome criteria (≥85 cm for men and ≥90 cm for women) for concordance between NAFLD and MASLD was also investigated. Results: According to the original criteria, the prevalence of MASLD in patients with NAFLD was 96.7%. Similarly, according to the Japanese waist circumference criteria, 96.2% of patients with NAFLD could be reclassified as those with MASLD. The concordance rate was significantly higher in the original criteria than in the Japanese criteria (p = 0.02). Conclusions: NAFLD could be considered MASLD using the original MASLD criteria in the Japanese population, and insights from NAFLD research could be applied to MASLD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Author

Suzuki, Keito, primary, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Matsumoto, Hiroaki, additional, Yamazaki, Yudai, additional, Uchihara, Naoki, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Keitoku, Taisei, additional, Okada, Risa, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Tamaki, Nobuharu, additional, Nakanishi, Hiroyuki, additional, Takahashi, Yuka, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2024
Full Text
View/download PDF

23. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study

Author

Kudo, Masatoshi, primary, Tsuchiya, Kaoru, additional, Shao, Yu-Yun, additional, Finn, Richard S., additional, Galle, Peter R., additional, Ducreux, Michel, additional, Cheng, Ann-Lii, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Take, Ryosuke, additional, Yamada, Kyoko, additional, Asakawa, Takashi, additional, Nakagawa, Yuki, additional, and Ikeda, Masafumi, additional

Published
2023
Full Text
View/download PDF

24. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Qin, Shukui, primary, Chen, Minshan, additional, Cheng, Ann-Lii, additional, Kaseb, Ahmed O, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam C, additional, Zhou, Jian, additional, Wang, Lu, additional, Wen, Xiaoyu, additional, Heo, Jeong, additional, Tak, Won Young, additional, Nakamura, Shinichiro, additional, Numata, Kazushi, additional, Uguen, Thomas, additional, Hsiehchen, David, additional, Cha, Edward, additional, Hack, Stephen P, additional, Lian, Qinshu, additional, Ma, Ning, additional, Spahn, Jessica H, additional, Wang, Yulei, additional, Wu, Chun, additional, Chow, Pierce K H, additional, Thompson, Alexander, additional, Danta, Mark, additional, Poursoltan, Pirooz, additional, Kiberu, Andrew, additional, Chittajallu, Renuka, additional, Sood, Siddarth, additional, Stauber, Rudolf, additional, Pinter, Matthias, additional, Peck-Radosavljevic, Markus, additional, Decaestecker, Jochen, additional, Cuyle, Pieter-Jan, additional, Verset, Gontran, additional, Van Vlierberghe, Hans, additional, De Azevedo, Sergio, additional, Andrade, Livia, additional, Cunha Júnior, Ademar, additional, Faria, Luiza, additional, Yen, Cheng Tzu, additional, Colli, Leandro, additional, Asselah, Jamil, additional, Kavan, Petr, additional, Marquez, Vladimir, additional, Brahmania, Mayur, additional, Li, Qiang, additional, Xing, Baocai, additional, Guo, Yabing, additional, Chen, Zhendong, additional, Zhao, Haitao, additional, Peng, Tao, additional, Wang, Liming, additional, Liu, Hongming, additional, Wu, Feixiang, additional, Qin, Lunxiu, additional, Zheng, Qichang, additional, Ying, Jieer, additional, Li, Haitao, additional, Wen, Tianfu, additional, Qin, Shukui, additional, Liu, Yunpeng, additional, Wang, Boqing, additional, Bai, Yuxian, additional, He, Yifu, additional, Zhao, Hong, additional, Zhou, Dong, additional, Dai, Chaoliu, additional, Teng, Gaojun, additional, Cui, Shuzhong, additional, Gao, Yi, additional, Zhang, Xizhi, additional, Lu, Zheng, additional, Yin, Tao, additional, Ding, Youming, additional, Jia, Weidong, additional, Xia, Yongxiang, additional, Sun, Beicheng, additional, Xia, Qiang, additional, Yuan, Yufeng, additional, Sun, Huichuan, additional, Shi, Xuetao, additional, Guzmán, Adrián, additional, Corrales, Luis, additional, Kral, Zdenek, additional, Priester, Peter, additional, Kubala, Eugen, additional, Blanc, Jean Frederic, additional, Bourliere, Marc, additional, Peron, Jean Marie, additional, Borg, Christophe, additional, Bronowicki, Jean-Pierre, additional, Ganne, Nathalie, additional, Decaens, Thomas, additional, Heurgue, Alexandra, additional, Trojan, Joerg, additional, Gonzalez-Carmona, Maria Angeles, additional, Roderburg, Christoph, additional, Ettrich, Thomas, additional, Schotten, Clemens, additional, Kandulski, Arne, additional, Yau, Thomas, additional, Chan, Lam, additional, Scartozzi, Mario, additional, Masi, Gianluca, additional, Fanello, Silvia, additional, Battezzati, Pier Maria, additional, Leonardi, Francesco, additional, Ghidini, Michele, additional, Morimoto, Manabu, additional, Hidaka, Hisashi, additional, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Kato, Naoya, additional, Hagihara, Atsushi, additional, Koga, Hironori, additional, Arakawa, Tomohiro, additional, Nakamura, Ikuo, additional, Kawamura, Yusuke, additional, Kawaoka, Tomokazu, additional, Shimada, Mitsuo, additional, Hasegawa, Kiyoshi, additional, Marusawa, Hiroyuki, additional, Nakamura, Shinchiro, additional, Hiraoka, Atsushi, additional, Hayashi, Hiromitsu, additional, Takeda, Shin, additional, Paik, Seung Woon, additional, Kim, Do Young, additional, Lee, Jung Il, additional, Jeong, Sook-Hyang, additional, Kim, Won, additional, Kim, Hyeyeong, additional, Chon, Hong Jae, additional, Cheong, Jaeyoun, additional, Yoon, Seung Kew, additional, Yoon, Jung-Hwan, additional, Villalobos, Ricardo, additional, Martinez Rodriguez, Jorge Luis, additional, Oyervides Juarez, Victor, additional, Hernández, Carlos Alberto, additional, Klumpen, Heinz-Josef, additional, de Vos-Geelen, Judith, additional, Gane, Edward, additional, Montenegro, Paola, additional, Torres Mattos, Cesar, additional, Janczewska, Ewa, additional, Kawecki, Maciej, additional, Nowakowska-Zajdel, Ewa, additional, Fedenko, Alexander, additional, Granov, Dmitrii, additional, Alyasova, Anna, additional, Sekacheva, Marina, additional, Ledin, Evgeny, additional, Samol, Jens, additional, Toh, Han Chong, additional, Calvo Campos, Mariona, additional, Gomez Martin, Carlos, additional, Lopez Lopez, Carlos, additional, Muñoz Martin, Andres Jesus, additional, Calleja Panero, Jose Luis, additional, Montero Alvarez, Jose Luis, additional, Reig Monzón, Maria, additional, Delgado Mingorance, Ignacio, additional, Minguez Rosique, Beatriz, additional, Cheng, Ann Lii, additional, Huang, Yi-Hsiang, additional, Lin, Shi-Ming, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Su, Wei-Wen, additional, Korphaisarn, Krittiya, additional, Maneenil, Kunlatida, additional, Samdaengpan, Chayanee, additional, Tharavichitkul, Ekkapong, additional, Ozguroglu, Mustafa, additional, Kose, Fatih, additional, Harputluoglu, Hakan, additional, Buchschacher, Gary, additional, Thuluvath, Paul, additional, Xiong, Henry, additional, Patel, Mital, additional, Gold, Philip, additional, Li, Daneng, additional, Brooks, Gabriel, additional, Masood, Ashiq, additional, Patel, Reema, additional, George, Ben, additional, Salgia, Reena, additional, Manji, Gulam, additional, Crow, Mary, additional, Kaseb, Ahmed, additional, Dugan, Matthew, additional, Kadakia, Kunal, additional, Kardosh, Adel, additional, Gibbs, John, additional, Shah, Ashesh, additional, and Burris III, Howard, additional

Published
2023
Full Text
View/download PDF

26. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.

Author

Ikeda, Masafumi, Yamashita, Tatsuya, Ogasawara, Sadahisa, Kudo, Masatoshi, Inaba, Yoshitaka, Morimoto, Manabu, Tsuchiya, Kaoru, Shimizu, Satoshi, Kojima, Yasushi, Hiraoka, Atsushi, Nouso, Kazuhiro, Aikata, Hiroshi, Numata, Kazushi, Sato, Tosiya, Okusaka, Takuji, and Furuse, Junji

Subjects
INTRA-arterial infusions, CISPLATIN, HEPATOCELLULAR carcinoma, CLINICAL trials, OVERALL survival
Abstract

Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim of this trial was to evaluate the efficacy and safety of lenvatinib in combination with HAIC using cisplatin in patients with advanced HCC. Methods: In this multicenter, open-labeled, single-arm, phase II trial, patients with advanced HCC categorized as Child-Pugh class A with no prior history of systemic therapy were enrolled. Patients received lenvatinib plus HAIC with cisplatin (lenvatinib: 12 mg once daily for patients ≥60 kg, 8 mg once daily for patients <60 kg; HAIC with cisplatin: 65 mg/m2, day 1, every 4–6 weeks, maximum of six cycles). The primary endpoint was the objective response rate (ORR) assessed using modified RECIST by the Independent Review Committee. The secondary endpoints were the ORR assessed using RECIST v1.1, progression-free survival, overall survival, and frequency of adverse events associated with the treatment. Results: A total of 36 patients were enrolled between September 2018 and March 2020. In the 34 evaluable patients, the ORR assessed by the Independent Review Committee using modified RECIST and RECIST v1.1 were 64.7% (95% confidence interval [CI]: 46.5–80.3%) and 45.7% (95% CI: 28.8–63.4%), respectively. The median progression-free survival and overall survival were 6.3 months (95% CI: 5.1–7.9 months) and 17.2 months (95% CI: 10.9 – not available, months), respectively. The main grade 3–4 adverse events were increased aspartate aminotransferase (34%), leukopenia (22%), increased alanine aminotransferase (19%), and hypertension (11%). Conclusion: Lenvatinib plus HAIC with cisplatin yielded a favorable ORR and overall survival and was well tolerated in patients with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population

Author

Kirino, Sakura, primary, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Takahashi, Yuka, additional, Higuchi, Mayu, additional, Itakura, Yoshie, additional, Tanaka, Yuki, additional, Inada, Kento, additional, Ishido, Shun, additional, Yamashita, Koji, additional, Nobusawa, Tsubasa, additional, Matsumoto, Hiroaki, additional, Hayakawa, Yuka, additional, Kakegawa, Tatsuya, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Kaneko, Shun, additional, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Okamoto, Ryuichi, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

28. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B

Author

Ishido, Shun, primary, Tamaki, Nobuharu, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Keitoku, Taisei, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Itakura, Jun, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

29. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

Author

Ikeda, Masafumi, primary, Yamashita, Tatsuya, additional, Ogasawara, Sadahisa, additional, Kudo, Masatoshi, additional, Inaba, Yoshitaka, additional, Morimoto, Manabu, additional, Tsuchiya, Kaoru, additional, Shimizu, Satoshi, additional, Kojima, Yasushi, additional, Hiraoka, Atsushi, additional, Nouso, Kazuhiro, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Sato, Tosiya, additional, Okusaka, Takuji, additional, and Furuse, Junji, additional

Published
2023
Full Text
View/download PDF

30. Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

Author

Ishido, Shun, primary, Tamaki, Nobuharu, additional, Inada, Kento, additional, Itakura, Jun, additional, Takahashi, Yuka, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Keitoku, Taisei, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

31. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease

Author

Ishido, Shun, primary, Tamaki, Nobuharu, additional, Takahashi, Yuka, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Keitoku, Taisei, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

33. The importance of regular screening for HCC in non-alcoholic steatohepatitis/non-alcoholic fatty liver disease

Author

Keitoku, Taisei, primary, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Ishido, Shun, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Huang, Daniel, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

35. Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy

Author

Nakanishi, Hiroyuki, Hayakawa, Yuka, Kubota, Youhei, Kurosaki, Masayuki, Osawa, Leona, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Okada, Mao, Wan, Wang, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Tamaki, Nobuharu, Yasui, Yutaka, Noda, Takamasa, Nakanishi, Kaoru, Tsuchiya, Kaoru, Itakura, Jun, Takahashi, Yuka, and Izumi, Namiki

Published
2020
Full Text
View/download PDF

36. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy

Author

Hayakawa, Yuka, primary, Tamaki, Nobuharu, additional, Nakanishi, Hiroyuki, additional, Kurosaki, Masayuki, additional, Tanaka, Yuki, additional, Inada, Kento, additional, Ishido, Shun, additional, Kirino, Sakura, additional, Yamashita, Koji, additional, Nobusawa, Tsubasa, additional, Matsumoto, Hiroaki, additional, Kakegawa, Tatsuya, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Kaneko, Shun, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Tsuchiya, Kaoru, additional, Okamoto, Ryuichi, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

38. Revisions of the clinical practice guidelines for hepatocellular carcinoma in 2021 version

Author

Takemura, Nobuyuki, primary, Tateishi, Ryosuke, additional, Yamashita, Tatsuya, additional, Watadani, Takeyuki, additional, Kaibori, Masaki, additional, Kubo, Shoji, additional, Shimada, Mitsuo, additional, Nagano, Hiroaki, additional, Hatano, Etsuro, additional, Aikata, Hiroshi, additional, Iijima, Hiroko, additional, Ueshima, Kazuomi, additional, Ohkawa, Kazuyoshi, additional, Genda, Takuya, additional, Tsuchiya, Kaoru, additional, Torimura, Takuji, additional, Ikeda, Masafumi, additional, Furuse, Junji, additional, Akahane, Masaaki, additional, Kobayashi, Satoshi, additional, Sakurai, Hideyuki, additional, Takeda, Atsuya, additional, Murakami, Takamichi, additional, Motosugi, Utaroh, additional, Matsuyama, Yutaka, additional, Kudo, Masatoshi, additional, and Hasegawa, Kiyoshi, additional

Published
2023
Full Text
View/download PDF

39. Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.

Author

Kudo, Masatoshi, primary, Aoki, Tomoko, additional, Ueshima, Kazuomi, additional, Tsuchiya, Kaoru, additional, Morita, Masahiro, additional, Hagiwara, Satoru, additional, Minami, Yasunori, additional, Ida, Hiroshi, additional, Nishida, Naoshi, additional, Ogawa, Chikara, additional, Tomonari, Tetsu, additional, Nakamura, Noriaki, additional, Kuroda, Hidekatsu, additional, Takebe, Atsushi, additional, Takeyama, Yoshifumi, additional, Hidaka, Masaaki, additional, Eguchi, Susumu, additional, Chan, Stephen Lam, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

40. IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.

Author

Kudo, Masatoshi, primary, Tsuchiya, Kaoru, additional, Shao, Yu Yun, additional, Finn, Richard S., additional, Galle, Peter R., additional, Ducreux, Michel, additional, Cheng, Ann-Lii, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Aoki, Kenichi, additional, Yamada, Kyoko, additional, Asakawa, Takashi, additional, Nakagawa, Yuki, additional, and Ikeda, Masafumi, additional

Published
2023
Full Text
View/download PDF

41. The impact of relative dose intensity on overall and progression-free survival during cabozantinib therapy for unresectable hepatocellular carcinoma.

Author

Nobusawa, Tsubasa, primary, Tsuchiya, Kaoru, additional, Yasui, Yutaka, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Ishido, Shun, additional, Yamada, Michiko, additional, Keitoku, Taisei, additional, Matsumoto, Hiroaki, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Tamaki, Nobuharu, additional, Nakanishi, Hiroyuki, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

42. Clinical utility of comprehensive genomic profiling in patients with unresectable primary liver cancer.

Author

Ishido, Shun, primary, Tsuchiya, Kaoru, additional, Suzuki, Keito, additional, Uchihara, Naoki, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Keitoku, Taisei, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Tamaki, Nobuharu, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Nakanishi, Hiroyuki, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

44. Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy

Author

Keitoku, Taisei, primary, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Inada, Kento, additional, Kirino, Sakura, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Ishido, Shun, additional, Yamada, Michiko, additional, Nobusawa, Tsubasa, additional, Matsumoto, Hiroaki, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Kaneko, Shun, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, Asahina, Yasuhiro, additional, Okamoto, Ryuichi, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

45. Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma

Author

Ishido, Shun, primary, Tsuchiya, Kaoru, additional, Kano, Yoshihito, additional, Yasui, Yutaka, additional, Takaura, Kenta, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Yamada, Michiko, additional, Matsumoto, Hiroaki, additional, Nobusawa, Tsubasa, additional, Keitoku, Taisei, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Tamaki, Nobuharu, additional, Takahashi, Yuka, additional, Nakanishi, Hiroyuki, additional, Sakurai, Urara, additional, Asahina, Yasuhiro, additional, Okamoto, Ryuichi, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

46. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

Author

Kato, Naoya, primary, Kudo, Masatoshi, additional, Tsuchiya, Kaoru, additional, Hagihara, Atsushi, additional, Numata, Kazushi, additional, Aikata, Hiroshi, additional, Inaba, Yoshitaka, additional, Kondo, Shunsuke, additional, Motomura, Kenta, additional, Okano, Naohiro, additional, Ikeda, Masafumi, additional, Morimoto, Manabu, additional, Kuroda, Shingo, additional, and Kimura, Akiko, additional

Published
2023
Full Text
View/download PDF

47. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

Author

Kudo, Masatoshi, primary, Aoki, Tomoko, additional, Ueshima, Kazuomi, additional, Tsuchiya, Kaoru, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Takita, Masahiro, additional, Hagiwara, Satoru, additional, Minami, Yasunori, additional, Ida, Hiroshi, additional, Nishida, Naoshi, additional, Ogawa, Chikara, additional, Tomonari, Tetsu, additional, Nakamura, Noriaki, additional, Kuroda, Hidekatsu, additional, Takebe, Atsushi, additional, Takeyama, Yoshifumi, additional, Hidaka, Masaaki, additional, Eguchi, Susumu, additional, Chan, Stephen L, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

48. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease

Author

Yamada-Shimizu, Michiko, primary, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Uchihara, Naoki, additional, Suzuki, Keito, additional, Tanaka, Yuki, additional, Miyamoto, Haruka, additional, Ishido, Shun, additional, Nobusawa, Tsubasa, additional, Matsumoto, Hiroaki, additional, Keitoku, Taisei, additional, Higuchi, Mayu, additional, Takaura, Kenta, additional, Tanaka, Shohei, additional, Maeyashiki, Chiaki, additional, Yasui, Yutaka, additional, Takahashi, Yuka, additional, Tsuchiya, Kaoru, additional, Nakanishi, Hiroyuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

50. L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis

Author

Nakanishi, Hiroyuki, Kurosaki, Masayuki, Tsuchiya, Kaoru, Nakakuki, Natsuko, Takada, Hitomi, Matsuda, Shuya, Gondo, Kouichi, Asano, Yu, Hattori, Nobuhiro, Tamaki, Nobuharu, Suzuki, Shoko, Yasui, Yutaka, Hosokawa, Takanori, Itakura, Jun, Takahashi, Yuka, and Izumi, Namiki

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results